383 related articles for article (PubMed ID: 20660600)
1. A combination of DR5 agonistic monoclonal antibody with gemcitabine targets pancreatic cancer stem cells and results in long-term disease control in human pancreatic cancer model.
Rajeshkumar NV; Rasheed ZA; García-García E; López-Ríos F; Fujiwara K; Matsui WH; Hidalgo M
Mol Cancer Ther; 2010 Sep; 9(9):2582-92. PubMed ID: 20660600
[TBL] [Abstract][Full Text] [Related]
2. Aspirin counteracts cancer stem cell features, desmoplasia and gemcitabine resistance in pancreatic cancer.
Zhang Y; Liu L; Fan P; Bauer N; Gladkich J; Ryschich E; Bazhin AV; Giese NA; Strobel O; Hackert T; Hinz U; Gross W; Fortunato F; Herr I
Oncotarget; 2015 Apr; 6(12):9999-10015. PubMed ID: 25846752
[TBL] [Abstract][Full Text] [Related]
3. Curaxin CBL0137 eradicates drug resistant cancer stem cells and potentiates efficacy of gemcitabine in preclinical models of pancreatic cancer.
Burkhart C; Fleyshman D; Kohrn R; Commane M; Garrigan J; Kurbatov V; Toshkov I; Ramachandran R; Martello L; Gurova KV
Oncotarget; 2014 Nov; 5(22):11038-53. PubMed ID: 25402820
[TBL] [Abstract][Full Text] [Related]
4. Notch signaling pathway targeted therapy suppresses tumor progression and metastatic spread in pancreatic cancer.
Yabuuchi S; Pai SG; Campbell NR; de Wilde RF; De Oliveira E; Korangath P; Streppel MM; Rasheed ZA; Hidalgo M; Maitra A; Rajeshkumar NV
Cancer Lett; 2013 Jul; 335(1):41-51. PubMed ID: 23402814
[TBL] [Abstract][Full Text] [Related]
5. Treatment with gemcitabine and TRA-8 anti-death receptor-5 mAb reduces pancreatic adenocarcinoma cell viability in vitro and growth in vivo.
DeRosier LC; Huang ZQ; Sellers JC; Buchsbaum DJ; Vickers SM
J Gastrointest Surg; 2006 Nov; 10(9):1291-300; discussion 1300. PubMed ID: 17114015
[TBL] [Abstract][Full Text] [Related]
6. Mesothelin blockage by Amatuximab suppresses cell invasiveness, enhances gemcitabine sensitivity and regulates cancer cell stemness in mesothelin-positive pancreatic cancer cells.
Matsuzawa F; Kamachi H; Mizukami T; Einama T; Kawamata F; Fujii Y; Fukai M; Kobayashi N; Hatanaka Y; Taketomi A
BMC Cancer; 2021 Feb; 21(1):200. PubMed ID: 33637083
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of glucose turnover by 3-bromopyruvate counteracts pancreatic cancer stem cell features and sensitizes cells to gemcitabine.
Isayev O; Rausch V; Bauer N; Liu L; Fan P; Zhang Y; Gladkich J; Nwaeburu CC; Mattern J; Mollenhauer M; Rückert F; Zach S; Haberkorn U; Gross W; Schönsiegel F; Bazhin AV; Herr I
Oncotarget; 2014 Jul; 5(13):5177-89. PubMed ID: 25015789
[TBL] [Abstract][Full Text] [Related]
8. Curcumin sensitizes pancreatic cancer cells to gemcitabine by attenuating PRC2 subunit EZH2, and the lncRNA PVT1 expression.
Yoshida K; Toden S; Ravindranathan P; Han H; Goel A
Carcinogenesis; 2017 Oct; 38(10):1036-1046. PubMed ID: 29048549
[TBL] [Abstract][Full Text] [Related]
9. Interleukin-4 cytotoxin therapy synergizes with gemcitabine in a mouse model of pancreatic ductal adenocarcinoma.
Shimamura T; Royal RE; Kioi M; Nakajima A; Husain SR; Puri RK
Cancer Res; 2007 Oct; 67(20):9903-12. PubMed ID: 17942922
[TBL] [Abstract][Full Text] [Related]
10. Multimodal Treatment Eliminates Cancer Stem Cells and Leads to Long-Term Survival in Primary Human Pancreatic Cancer Tissue Xenografts.
Hermann PC; Trabulo SM; Sainz B; Balic A; Garcia E; Hahn SA; Vandana M; Sahoo SK; Tunici P; Bakker A; Hidalgo M; Heeschen C
PLoS One; 2013; 8(6):e66371. PubMed ID: 23825539
[TBL] [Abstract][Full Text] [Related]
11. A humanized anti-IGF-1R monoclonal antibody (R1507) and/or metformin enhance gemcitabine-induced apoptosis in pancreatic cancer cells.
Kawanami T; Takiguchi S; Ikeda N; Funakoshi A
Oncol Rep; 2012 Mar; 27(3):867-72. PubMed ID: 22200743
[TBL] [Abstract][Full Text] [Related]
12. JNK pathway inhibition selectively primes pancreatic cancer stem cells to TRAIL-induced apoptosis without affecting the physiology of normal tissue resident stem cells.
Recio-Boiles A; Ilmer M; Rhea PR; Kettlun C; Heinemann ML; Ruetering J; Vykoukal J; Alt E
Oncotarget; 2016 Mar; 7(9):9890-906. PubMed ID: 26840266
[TBL] [Abstract][Full Text] [Related]
13. Phase 2, multicenter, open-label study of tigatuzumab (CS-1008), a humanized monoclonal antibody targeting death receptor 5, in combination with gemcitabine in chemotherapy-naive patients with unresectable or metastatic pancreatic cancer.
Forero-Torres A; Infante JR; Waterhouse D; Wong L; Vickers S; Arrowsmith E; He AR; Hart L; Trent D; Wade J; Jin X; Wang Q; Austin T; Rosen M; Beckman R; von Roemeling R; Greenberg J; Saleh M
Cancer Med; 2013 Dec; 2(6):925-32. PubMed ID: 24403266
[TBL] [Abstract][Full Text] [Related]
14. Combination of salinomycin and gemcitabine eliminates pancreatic cancer cells.
Zhang GN; Liang Y; Zhou LJ; Chen SP; Chen G; Zhang TP; Kang T; Zhao YP
Cancer Lett; 2011 Dec; 313(2):137-44. PubMed ID: 22030254
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of CD47 Effectively Targets Pancreatic Cancer Stem Cells via Dual Mechanisms.
Cioffi M; Trabulo S; Hidalgo M; Costello E; Greenhalf W; Erkan M; Kleeff J; Sainz B; Heeschen C
Clin Cancer Res; 2015 May; 21(10):2325-37. PubMed ID: 25717063
[TBL] [Abstract][Full Text] [Related]
16. Targeting of pancreatic and prostate cancer stem cell characteristics by Crambe crambe marine sponge extract.
Ottinger S; Klöppel A; Rausch V; Liu L; Kallifatidis G; Gross W; Gebhard MM; Brümmer F; Herr I
Int J Cancer; 2012 Apr; 130(7):1671-81. PubMed ID: 21544815
[TBL] [Abstract][Full Text] [Related]
17. Multifunctionalized iron oxide nanoparticles for selective targeting of pancreatic cancer cells.
Trabulo S; Aires A; Aicher A; Heeschen C; Cortajarena AL
Biochim Biophys Acta Gen Subj; 2017 Jun; 1861(6):1597-1605. PubMed ID: 28161480
[TBL] [Abstract][Full Text] [Related]
18. Intrinsic gemcitabine resistance in a novel pancreatic cancer cell line is associated with cancer stem cell-like phenotype.
Hu G; Li F; Ouyang K; Xie F; Tang X; Wang K; Han S; Jiang Z; Zhu M; Wen D; Qin X; Zhang L
Int J Oncol; 2012 Mar; 40(3):798-806. PubMed ID: 22076649
[TBL] [Abstract][Full Text] [Related]
19. Combined targeted treatment to eliminate tumorigenic cancer stem cells in human pancreatic cancer.
Mueller MT; Hermann PC; Witthauer J; Rubio-Viqueira B; Leicht SF; Huber S; Ellwart JW; Mustafa M; Bartenstein P; D'Haese JG; Schoenberg MH; Berger F; Jauch KW; Hidalgo M; Heeschen C
Gastroenterology; 2009 Sep; 137(3):1102-13. PubMed ID: 19501590
[TBL] [Abstract][Full Text] [Related]
20. The novel c-Met inhibitor cabozantinib overcomes gemcitabine resistance and stem cell signaling in pancreatic cancer.
Hage C; Rausch V; Giese N; Giese T; Schönsiegel F; Labsch S; Nwaeburu C; Mattern J; Gladkich J; Herr I
Cell Death Dis; 2013 May; 4(5):e627. PubMed ID: 23661005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
